natgillin/translations-raw huggingface dataset:
** Seroconversion was defined as an SRH area ≥25 mm2 for subjects who were seronegative at baseline (Day 1 SRH area ≤4 mm2) or a significant (at least 50%) increase in SRH area for subjects who were seropositive at baseline (Day 1 SRH area >4 mm2) *** geometric mean ratios (GMRs) of SRH 
** Serokonverzija je definirana kao SRH površina ≥25 mm2 u ispitanika koji su bili seronegativni na početku ispitivanja (SRH površina 1. dana ≤4 mm2) ili značajni (najmanje 50%-tni) porast SRH površine za ispitnike koji su bili seropozitivni na početku ispitivanja (površina SRH 1. dana >4 mm2) *** GMR vrijednosti SRH ° izmjereno HI analizom ≥40 °° GMR vrijednosti HI-a
In children and adolescents, pain was the most frequently reported solicited local reaction, and fatigue and headache were the most commonly reported solicited systemic reactions. 
dok su umor i glavobolja bili najčešće prijavljene izazvane sistemske reakcije.
V87P11 Elderly (>61-89 years)a N=142 
V87P11 Starije osobe (6189 godina) a N=142
Adults (20- 60 years)a 
Odrasli (20-60 godina) a
Seroconversion rates against homologous A/turkey/Turkey/1/2005 ranged from 37.50% to 43.10% in healthy adults, and from 19.18% to 26.47% in adults with immunosuppressive or underlying medical conditions, respectively; seroconversion rates ranged from 21.43% to 30.65% in healthy elderly subjects, and from 24.49% to 27.86% in elderly subjects with immunosuppressive or underlying medical conditions. 
Stope serokonverzije protiv homolognog virusa podtipa A/turkey/Turkey/1/2005 kretale su se od 37,50% do 43,10% u zdravih odraslih, i od 19,18% do 26,47% u odraslih s postojećom imunosupresijom ili medicinskim stanjem; stope serokonverzije su se kretale od 21,43% do 30,65% u zdravih odraslih ispitanika, i od 24,49% do 27,86% u starijih ispitanika s imunosupresijom ili postojećim medicinskim stanjem.
MN results for A/Indonesia/5/2005 revealed a seroprotection rate of 38% (31-45) in adults (18-60 years) and 14% (8-20) in elderly (>61 years); a seroconversion rate of 58% (50-65) in adults and 30% (23-38) in elderly and finally a GMR of 4.67 (3.95-5.56) in adults and 2.19 (1.86-2.58) in elderly. 
Rezultati MN analize za virus A/Indonesia/5/2005 pokazali su stopu seroprotekcije od 38% (31-45) u odraslih osoba (18-60 godina) i 14% (8-20) u starijih osoba (≥61 godina): stopa serokonverzije od 58% (50-65) u odraslih osoba i 30% (23-38) u starijih osoba te omjer srednje geometrijske vrijednosti (GMR) od 4,67 (3,95-5,56) u odraslih osoba i 2,19 (1,86-2,58) u starijih osoba.
Efficacy against challenge with virus homologous and heterologous to vaccine strains was evaluated in the ferret model. 
Djelotvornost je procijenjena na modelu tvorova pokusom s virusom koji je homologan i heterologan sojevima cjepiva.
Post-marketing surveillance No post-marketing surveillance data are available following AFLUNOV administration. 
Nema dostupnih podataka o praćenju nakon stavljanja gotovog lijeka u promet nakon primjene cjepiva AFLUNOV.
and a type of paralysis known as Guillain-Barré Syndrome. 
• Neurološki poremećaji kao što su encefalomijelitis (upala središnjeg živčanog sustava) i vrsta paralize koja se naziva Guillain-Barréov sindrom
MN results against homologous A/Vietnam/1194/2004 indicate a seroprotection and seroconversion rate ranging from 57% (50-64) to 79% (68-87) and 55% (48-62) to 58% (47-69), respectively. 
Rezultati MN analize na homologni virus A/Vietnam/1194/2004 upućuju na stopu seroprotekcije i serokonverzije u rasponu od 57% (50-64) do 79% (68-87), odnosno od 55% (48-62) do 58% (47-69).
a actual age range of population enrolled * Seroprotection: SRH area≥25 mm2 
a trenutni raspon dobi populacije uključene u ispitivanje * mjereno SRH analizom seroprotekcije: SRH površina ≥25 mm2, serokonverzija: SRH površina ≥25 mm2
The vaccine will be injected into the muscles of the upper arm (deltoid muscle). 
Cjepivo se injicira u mišiće nadlaktice (deltoidni mišić).
• Urticaria (hives). 
• Koprivnjača (urtikarija)
Nervous system disorders 
Poremećaji živčanog sustava glavobolja konvulzije
Seroconversion rate (95%CI)° 
Stopa serokonverzije (95%CI)°
MicroNeutralisation (MN) results against homologous A/Vietnam/1194/2004) indicate a seroprotection and seroconversion rate ranging from 67% (60-74) to 85% (78-90) and 65% (58-72) to 83% (77-89), respectively. 
Rezultati mikroneutralizacije (MN) na homologni virus A/Vietnam/1194/2004 upućuju na stopu seroprotekcije i serokonverzije u rasponu od 67% (60-74) do 85% (78-90), odnosno od 65% (58-72) do 83% (77-89).
AFLUNOV may contain trace residues of egg and chicken proteins, ovalbumin, kanamycin, neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide which are used during the manufacturing process (see section 4.3). 
neomicinsulfata, formaldehida i cetiltrimetilamonijeva bromida koji se upotrebljavaju tijekom postupka proizvodnje (vidjeti dio 4.3).
Cross-reactive immune response elicited by A/Vietnam/1194/2004 against A/turkey/Turkey/1/2005 and A/Indonesia/5/2005 
Križno reaktivan imunološki odgovor izazvan virusom A/Vietnam/1194/2004 na viruse A/turkey/Turkey/1/2005 i A/Indonesia/5/2005
Neurological disorders, such as neuralgia, paraesthesia, convulsions and neuritis. 
Poremećaji živčanog sustava Glavobolja, omaglica, somnolencija, sinkopa, neurološki poremećaji poput neuralgije, parestezije,
In Study V87P11, MN results against homologous A/turkey/Turkey/1/2005 indicate a seroprotection and seroconversion rate of 68% (59-75) and 81% (74-87), respectively. 
Rezultati MN analize u Studiji V87P11 na homologni virus A/turkey/Turkey/1/2005 upućuju na stopu seroprotekcije i serokonverzije od 68% (59-75) odnosno 81% (74-87).
Elderly (61-84 years)a 
Starije osobe (61-84 godine) a
ANNEX II A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
PRILOG II. A. PROIZVOĐAČI BIOLOŠKE DJELATNE TVARI I PROIZVOĐAČ(I) ODGOVORAN(NI) ZA PUŠTANJE SERIJE LIJEKA U PROMET
Study V87P11 A/turkey/Turkey/1/2005 21 days after 2nd dose N=182 
Studija V87P11 A/turkey/Turkey/1/2005 21 dan nakon 2. doze N=182
Elderly (61-79 years)a 
Starije osobe (61-79 godina) a
Study V87P3 21 days after 2nd dose N=30 
Studija V87P3 21 dan nakon 2. doze N=30
• Shivering 
• Trnci
Study V87P1 Elderly booster after 2nd dose 
Studija V87P1 starije osobe booster nakon 2. doze
Study V87P11 A/turkey/Turkey/1/2005 21 days after 2nd dose N=132c 
Studija V87P11 A/turkey/Turkey/1/2005 21 dan nakon 2. doze N=132c
Urticaria 
Kašalj
Study V87P13 21 days after 2nd dose N=197 
Studija V87P13 21 dan nakon 2. doze N=197
Study V87P2 Adults booster after 2nd dose 
Studija V87P2 odrasli booster nakon 2. doze
% SC (95% CI) Day 43 
% seroprotekcije (95% CI) 43. dan
The seroprotection rate*, seroconversion rate** and the seroconversion factor*** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 measured by SRH assays were as follows: 
Stopa seroprotekcije*, stopa serokonverzije** i čimbenik serokonverzije*** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 izmjereni SRH analizama bili su sljedeći:
Limited data were obtained from women who became pregnant during the course of clinical trials with AFLUNOV or similar pandemic H1N1v vaccines adjuvanted with MF59C.1. 
AFLUNOV ili sličnim pandemijskim H1N1v cjepivima adjuvantiranim s MF59C.1.
Geometric Mean Area (95%CI)* Seroprotection rate (95%CI)* Seroconversion rate (95%CI)* Seroconversion factor (95%CI)** 
Srednja geometrijska vrijednost površine (95% CI)* Stopa seroprotekcije (95% CI)* Stopa serokonverzije (95% CI)* Faktor serokonverzije (95% CI)**
The seroprotection rate*, seroconversion rate** and the seroconversion factor*** for anti-HA antibody to H5N1 A/Vietnam/1194/2004 and to H5N1 A/turkey/Turkey/1/2005 in the adults measured by SRH assay was as follows: 
Stopa seroprotekcije*, stopa serokonverzije** i čimbenik serokonverzije*** za anti-HA protutijela na virus H5N1 A/Vietnam/1194/2004 i na virus H5N1 A/turkey/Turkey/1/2005 u odraslih osoba izmjereni SRH analizom bili su sljedeći:
AFLUNOV suspension for injection in pre-filled syringe. 
AFLUNOV suspenzija za injekciju u napunjenoj štrcaljki.
Elderly (61-91 years)a 
Starije osobe (61-91 godina) a
Seroprotection rate*, seroconversion rate** and the seroconversion factor*** for anti-HA antibodies to H5N1 A/turkey/Turkey/1/2005 after the 2nd dose in adults 18-60 years of age, measured by SRH and HI assays were as follows: 
Stopa seroprotekcije*, stopa serokonverzije** i čimbenik serokonverzije*** za anti-HA protutijela na virus H5N1 A/turkey/Turkey/1/2005 nakon 2. doze u odraslih osoba u dobi od 18 do 60 godina, izmjereni SRH i HI analizama bili su sljedeći:
History of an anaphylactic (i.e. life-threatening) reaction to any of the constituents or trace residues (egg and chicken proteins, ovalbumin, kanamycin and neomycin sulphate, formaldehyde and cetyltrimethylammonium bromide) of this vaccine. 
Anamneza anafilaktičke (tj. po život opasne) reakcije na bilo koji sastojak ovog cjepiva ili na ostatne tvari koje se u cjepivu nalaze u tragovima (jaja i pileće proteine, ovalbumin, kanamicin, neomicinsulfat, formaldehid i cetiltrimetilamonijev bromid.
Study V87P1 Adults booster after 2nd dose 
Studija V87P1 odrasli booster nakon 2. doze
Breast-feeding 
Limfadenopatija
Seroprotection rate*, seroconversion rate** and the seroconversion factor*** for anti-HA antibodies to H5N1 A/ Indonesia/5/2005 and A/Vietnam/1194/2004 after the 2nd dose in adults (18-60 years) and elderly (> 61years), measured by SRH and HI assays were as follows: Anti-HA antibody 
Stopa seroprotekcije*, stopa serokonverzije** i čimbenik serokonverzije*** za anti-HA protutijela na viruse H5N1 A/ Indonesia/5/2005 i A/Vietnam/1194/2004 nakon 2. doze u odraslih osoba (18-60 godina) i starijih osoba (≥61 godina), izmjereni SRH i HI analizama bili su sljedeći:
Cardiac disorders Palpitation, tachycardia. 
Palpitacije, tahikardija
% SP (95% CI) Day 43 GMR Day 43 to Day 1 % SC (95% CI)Day 43 
% seroprotekcije (95% CI) 43. dan Omjer srednje geometrijske vrijednosti (GMR) 43. dan do 1. dan
Injection site swelling, Injection site pain, Injection site induration, Injection site redness, Fatigue 
otvrdnuće na mjestu injekcije, crvenilo na mjestu injekcije, umor ekhimoza na mjestu injekcije,
assays) and reduced seroprotection rates in adults and elderly (≥ 61 years old) subjects with underlying medical or immunosuppressive conditions, suggest that AFLUNOV may not elicit the same level of protection against A/H5N1 strain as compared to healthy adults (see section 4.4). 
U oba ispitivanja, V87_25 i V87_26, niže razine protutijela (izmjerenih analizom HI, SRH i MN) i smanjene stope seroprotekcije u odraslih i starijih ispitanika (≥61 godina) s postojećim medicinskim stanjem ili stanjem imunosupresije, upućuju na to da cjepivo AFLUNOV ne mora izazvati jednaku razinu zaštite protiv soja virusa A/H5N1 kao u zdravih odraslih (vidjeti dio 4.4).
(A/Vietnam/1194/2004) dose, all vaccine schedule groups after 3 weeks from the 2nd vaccination achieved high levels of antibodies as evaluated with SRH. 
Tri tjedna nakon 2. cijepljenja su u svim skupinama, određenim prema rasporedu cijepljenja, postignute visoke razine antitijela kako je procijenjeno s SRH.
The seroprotection rate*, seroconversion rate** and the seroconversion factor*** for anti-HA antibody to H5N1 (A/Vietnam/1194/2004 and to A/ turkey/Turkey/1/2005) in subjects aged 61 years and older (limited number of subjects were above 70 years of age; n=123) measured by SRH assay assessed in three clinical studies were as follows: 
Stopa seroprotekcije*, stopa serokonverzije** i čimbenik serokonverzije*** za anti-HA protutijela na virus H5N1 (A/Vietnam/1194/2004 i na virus A/turkey/Turkey/1/2005) u ispitanika u dobi od 61 godinu i starijih (ograničen broj ispitanika bio je stariji od 70 godina; N=123) izmjereni SRH
Fainting can occur following, or even before, any needle injection. 
Nakon, ili čak i prije bilo kojeg uboda iglom može se javiti nesvjestica.
• Fever and nausea 
• Vrućica i mučnina • Opće loše osjećanje
Vascular disorders Vasculitis with transient renal involvement. 
Krvožilni poremećaji Vaskulitis s prolaznom zahvaćenošću bubrega
GMR (95% CI) Day 43 to Day 1 
Omjer srednje geometrijske vrijednosti (GMR) (95% CI) 43. dan do 1. dan
There is no information on administration of AFLUNOV with noninfluenza vaccines. 
Nema podataka o primjeni cjepiva AFLUNOV s cjepivima koja nisu cjepiva protiv gripe.
• Pain at the site of injection 
• Bol na mjestu injekcije
• Nausea 
• Svrbež
• if you have previously had a sudden life-threatening allergic reaction to any ingredient of AFLUNOV (listed in section 6) or to any of the substances that may be present in trace amounts as follows: egg and chicken protein, ovalbumin, formaldehyde, kanamycin and neomycin sulphate (antibiotics) or cetyltrimethylammonium bromide (CTAB). 
AFLUNOV (navedeni u dijelu 6) ili na bilo koju tvar koja može biti prisutna u tragovima kako slijedi: jaje i pileće bjelančevine, ovalbumin, formaldehid, kanamicin i neomicinsulfat (antibiotici) ili cetiltrimetilamonijev bromid (CTAB).
Anti-HA antibody Study V87P12 21 days after 2nd dose N=60 
Studija V87P12 21 dan nakon 2. doze N=60
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)** Seroconversion factor (95%CI)*** a Ages 62-88 years; b Ages 61-68 years; c Ages 61-89 years * Seroprotection: SRH area ≥ 25 mm2 
a dob 62-88 godina; b dob 61-68 godina; c dob 61-89 godina * Seroprotekcija: SRH površina ≥25 mm2 ** Serokonverzija je definirana kao SRH površina ≥25 mm2 u ispitanika koji su bili seronegativni na početku ispitivanja (SRH površina 1. dana ≤4 mm2) ili značajni (najmanje 50%-tni) porast
** geometric mean ratios of SRH 
dana >4 mm2) *** omjeri srednje geometrijske vrijednosti (GMR, engl. geometric mean ratios) SRH-a
Baseline Serostatus 
Početni serostatus
Seroprotection rate (95%CI)* Seroconversion rate (95%CI)** Seroconversion factor (95%CI)*** 
Stopa seroprotekcije (95%CI)* Stopa serokonverzije (95%CI)**
Skin and subcutaneous tissue disorders Erythema multiforme. 
Poremećaji kože i potkožnog tkiva znojenje urtikarija oticanje oka
Reporting of side effects 
Pomoćne tvari s pomoćnim učinkom
Study V87P1 A/Vietnam/1194/2004 21 days after 2nd dose N=84a 
Studija V87P1 A/Vietnam/1194/200421 dan nakon 2. doze N=84a
Healthy 
Zdravi
Geometric mean area*, seroprotection rate*, seroconversion rate* and the seroconversion factor** for anti-HA antibody to H5N1 A/turkey/Turkey/1/2005 measured by SRH assays 21 days after the 2nd dose were as follows: 
Srednja geometrijska vrijednost površine*, stope seroprotekcije*, stope serokonverzije* i faktora serokonverzije** za anti-HA protutijelo na H5N1 A/turkey/Turkey/1/2005 mjerenom analizom SRH
Study V87P1 A/Vietnam/1194/2004 21 days after 2nd dose N=149 
Studija V87P1 A/Vietnam/1194/2004 21 dan nakon 2. doze N=149
In trial V87_25 and V87_26, 96 and 67 subjects, respectively, were over the age of 70 years. 
U ispitivanju V87_25 bilo je 96 ispitanika starijih od 70 godina, dok ih je u ispitivanju V87_26 bilo 67. U oba ispitivanja su analize HI, SRH i MN nakon prve kao i nakon druge primijenjene doze pokazale imunogenost cjepiva AFLUNOV.
A clinical trial (V87P6) was conducted with AFLUNOV (A/Vietnam/1194/2004) in 471 children from 6 months to 17 years of age. 
(A/Vietnam/1194/2004) u 471 djeteta dobi od 6 mjeseci do 17 godina.
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=210b 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=210b
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=128 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=128
Muscoskeletal, connective tissue and bone disorders Muscular weakness, pain in extremities. 
Slabost mišića, bol u udovima
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=66 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=66
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=69 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=69
** Seroconversion was defined as an SRH area ≥25 mm2 for subjects who were seronegative at baseline (Day 1 SRH area ≤4 mm2) or a significant (at least 50%) increase in SRH area for subjects who were seropositive at baseline (Day 1 SRH area >4 mm2) *** GMRs of SRH 
(95%CI)°° * Seroprotekcija: SRH površina ≥25 mm2 ** Serokonverzija je definirana kao SRH površina ≥25 mm2 u ispitanika koji su bili seronegativni na početku ispitivanja (SRH površina 1. dana ≤4 mm2) ili značajni (najmanje 50%-tni) porast
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=143 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=143
Influenza like illness 
Zaštita od influence
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=197 
Studija V87P13 A/Vietnam/1194/2004 21 dan nakon 2. doze N=197
• Headache 
• Glavobolja • Umor
Respiratory disorders Cough. 
Čimbenik serokonverzije
• Eye swelling 
• Oticanje oka
* measured by SRH assay seroprotection: SRH area ≥25 mm2, seroconversion: SRH area ≥25 mm2 for subjects with a baseline SRH area ≤4 mm2 or a minimum 50% increase in SRH area for subjects with >4 mm2. 
za ispitanike s početnom vrijednošću SRH površine ≤4 mm2 ili minimalni porast od 50% SRH površine za ispitanike s >4 mm2. ** omjeri srednje geometrijske vrijednosti SRH
They should not be used during pregnancy and breastfeeding. 
Ne smiju se koristiti tijekom trudnoće i dojenja.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU. 
To znači da postoje bibliografski podaci koji pružaju znanstvene dokaze o njihovoj djelotvornosti i sigurnosti kada se koriste na opisani način i obuhvaćaju razdoblje od najmanje 10 godina u EU.
Castor oil medicines should only be used in adults, and should not be taken for longer than one week without medical supervision. 
Lijekovi od ricinusovog ulja smiju se primjenjivati samo u odraslih osoba i ne smiju se koristiti dulje od jednog tjedna bez medicinskog nadzora.
This means that the oil is extracted from the seeds by crushing and pressing them without heating. 
To znači da se ulje ekstrahira iz sjemenki drobljenjem i prešanjem bez zagrijavanja.
5 April 2016 EMA/108531/2016 
EMA/108531/2016
Castor oil EMA/108531/2016 
Ricinusovo ulje EMA/108531/2016
These include nausea, vomiting abdominal (belly) pain and severe diarrhoea. 
One uključuju mučninu, povraćanje, abdominalne bolove (bol u trbuhu) i težak proljev.
This increases the water content of stools, making them softer and easier to pass. 
Time se povećava sadržaj vode u stolici, čime ona postaje mekša i lakše prolazi kroz crijeva.
Castor oil medicines should not be taken in case of obstruction or narrowing of the gut, atony (loss of normal movement in the gut muscle), appendicitis (inflammation of the appendix, a small organ connected to the bowel), inflammatory diseases of the colon (the lower part of the bowel), unexplained abdominal pain and severe dehydration. 
Lijekovi koji sadrže ricinusovo ulje ne smiju se uzimati u slučaju opstrukcije ili suženja crijeva, atonije (gubitka normalnih kretnji mišića crijeva), apendicitisa (upala crvuljka („slijepog crijeva”), malog organa spojenog s crijevima), upale debelog crijeva (donjeg dijela crijeva), neobjašnjenih abdominalnih bolova i teške dehidracije.
Any applications for the licensing of medicines containing castor oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC. 
Svi zahtjevi za odobrenje lijekova koji sadrže ricinusovo ulje moraju se podnijeti nacionalnim tijelima nadležnima za lijekove, koja ocjenjuju zahtjev za biljni lijek i uzimaju u obzir znanstvene zaključke HMPC-a.
What is castor oil? 
Što je ricinusovo ulje?
Further information on the HMPC assessment of castor oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Dodatne informacije o HMPC-ovoj ocjeni lijekova koji sadrže ricinusovo ulje, uključujući pojedinosti zaključaka Povjerenstva, mogu se pronaći pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
How does castor oil work as a medicine? 
Kako ricinusovo ulje djeluje kao lijek?
When ingested, castor oil is broken down into ricinoleic acid which works by reducing absorption of fluid and salts in the small intestine (the upper part of the bowel). 
Nakon gutanja, ricinusovo ulje razgrađuje se na ricinoleatnu kiselinu, koja djeluje tako što smanjuje apsorpciju tekućina i soli u tankom crijevu (gornjem dijelu crijeva).
Castor oil 
Ricinusovo ulje
This summary is not intended to provide practical advice on how to use medicines containing castor oil. 
Svrha ovog sažetka nije davati praktične savjete o načinu primjene lijekova koji sadrže ricinusovo ulje.
Further information on the risks associated with castor oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use. 
Više o rizicima povezanima s lijekovima koji sadrže ricinusovo ulje, uključujući odgovarajuće mjere opreza za njihovu sigurnu primjenu, možete pronaći u monografiji pod karticom „All documents” na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Herbal medicines for human use.
Herbal medicines containing these castor oil preparations are usually available in solid or liquid forms to be taken by mouth. 
Biljni lijekovi koji sadrže te pripravke ricinusovog ulja najčešće su dostupni u krutom ili tekućem obliku i uzimaju se kroz usta.
In one of the studies the effects of castor oil capsules were similar to those of senna capsules (another herbal preparation commonly used to treat constipation). 
U jednom od ispitivanja učinak kapsula s ricinusovim uljem bio je sličan učinku kapsula sa senom (drugi biljni pripravak koji se često primjenjuje u liječenju zatvora).
Castor oil preparations may also be found in combination with other herbal substances in some herbal medicines. 
Pripravci ricinusovog ulja mogu postojati također i u kombinaciji s drugim biljnim tvarima u nekim biljnim lijekovima.
Information on the use and licensing of castor oil medicines in EU Member States should be obtained from the relevant national authorities. 
Informacije o primjeni i davanju odobrenja za lijekove koji sadrže ricinusovo ulje u državama članicama EU-a mogu se dobiti od nadležnih nacionalnih tijela.
The HMPC conclusions on the use of these castor oil medicines as laxatives are based on their ‘wellestablished use'. 
Zaključci HMPC-a o primjeni ovih lijekova koji sadrže ricinusovo ulje kao laksativa temelje se na njihovoj „provjerenoj medicinskoj uporabi”.
In its assessment, the HMPC considered two clinical studies which showed a laxative effect for castor oil medicines in constipated patients. 
Prilikom svoje ocjene HMPC je razmotrio dva klinička ispitivanja koja su pokazala laksativni učinak lijekova s ricinusovim uljem u bolesnika sa zatvorom.
The HMPC concluded that these castor oil preparations can be used for short term as laxatives for occasional constipation. 
HMPC je zaključio da se ovi pripravci ricinusovog ulja mogu kratkotrajno koristiti kao laksativi kod povremenog zatvora.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of castor oil. 
Ovaj dokument predstavlja sažetak znanstvenih zaključaka Povjerenstva za biljne lijekove (HMPC) u pogledu medicinske primjene ricinusovog ulja.
In addition, castor oil stimulates movement in the intestines which will help to pass the stools. 
Osim toga, ricinusovo ulje stimulira crijevne kretnje, što pomaže pražnjenju stolice.